Patent details
LUC00289 Product Name: tézépélumab
Basic Information
- Publication number:
- LUC00289
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
- EP088303623
- Legal Status:
- Inactive
- Application number:
- LUC00289
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
- Marketing Authorization Number:
- EU/1/22/1677
- Marketing Authorization Type:
- Marketing Authorization Date:
- 20/09/2022
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
- Luxembourg (LU)
Dates
- Filing date:
- 09/12/2022
- First Marketing Authorization date:
- 20/09/2022
- Grant date:
- 12/05/2025
- Activation date:
- Publication date:
- 09/12/2022
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 09/09/2033
- SPC Extension Expiration:
- 09/09/2033
- Rejection date:
- Withdrawal date:
Owner
- From:
- 09/12/2022
- Name:
- AMGEN INC.
- Address:
- One Amgen Center Drive, Thousand Oaks, CA 91320, United States (US)
Agent
- Name:
- OFFICE FREYLINGER S.A.
- From:
- 09/12/2022
- Address:
- Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
- To:
Publication
Bulletin
- Bulletin Heading:
- SPC1
- Bulletin edition number:
- 2023/01
- Publication date:
- 03/01/2023
- Description:
- Section C : Published requests for Supplementary Protection Certificates – I1 publication
Annual Fees
- Annual Fee Due Date:
- 02/10/2028
- Annual Fee Number:
- 21
- Annual Fee Amount:
- 410 Euro
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|---|---|
| 09/12/2022 | Application Form | 3 |
| 09/12/2022 | Marketing authorization | 3 |
| 09/12/2022 | Summary of the product caracteristics | 35 |
| 09/12/2022 | MA publication | 18 |
| 09/12/2022 | Outgoing Correspondence | 1 |
| 09/12/2022 | Publication | 1 |
| 12/05/2025 | Publication | 1 |
| 12/05/2025 | Certificate | 1 |
| 12/05/2025 | Outgoing Correspondence | 1 |